Saltar al contenido
Merck

1420006

USP

Levodopa Related Compound B

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

DL-3-O-Methyldopa, 3-Methoxytyrosine

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Acerca de este artículo

Fórmula empírica (notación de Hill):
C10H13NO4
Número CAS:
Peso molecular:
211.21
MDL number:
UNSPSC Code:
41116107
NACRES:
NA.24
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle


grade

pharmaceutical primary standard

agency

USP

API family

levodopa

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

NC(Cc1cc(c(cc1)O)OC)C(=O)O

InChI

1S/C10H13NO4/c1-15-9-5-6(2-3-8(9)12)4-7(11)10(13)14/h2-3,5,7,12H,4,11H2,1H3,(H,13,14)

InChI key

PFDUUKDQEHURQC-UHFFFAOYSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levodopa Related Compound B USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
  • Carbidopa and Levodopa Orally Disintegrating Tablets
  • Levodopa
  • Carbidopa and Levodopa Tablets
  • Carbidopa and Levodopa Extended-Release Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.


Still not finding the right product?

Explore all of our products under Levodopa Related Compound B


Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

No data available

flash_point_c

No data available



Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos



Stephanie L Merhar et al.
Pediatrics, 116(5), 1226-1230 (2005-11-03)
Chronic bilirubin encephalopathy, characterized clinically by extrapyramidal movement abnormalities, vertical gaze abnormalities, and hearing loss, results from neuronal injury after marked hyperbilirubinemia in term and preterm infants. In premature infants, bilirubin staining of specific brain structures has been described at
Yoritaka Onzawa et al.
Biological & pharmaceutical bulletin, 35(8), 1244-1248 (2012-08-07)
It has been well known that 3-O-methyldopa (3-OMD) is a metabolite of L-3,4-dihydroxyphenylalanine (L-DOPA) formed by catechol O-methyltransferase (COMT), and 3-OMD blood level often reaches higher than physiological level in Parkinson's disease (PD) patients receiving long term L-DOPA therapy. However
Thomas Müller et al.
Naunyn-Schmiedeberg's archives of pharmacology, 383(6), 627-633 (2011-05-03)
Elevation of plasma total homocysteine concentrations were observed in levodopa/dopa decarboxylase inhibitor (DDI)-treated patients with Parkinson's disease (PD). Degradation of levodopa to 3-O-methyldopa via the enzyme catechol-O-methyltransferase (COMT) is a methyl group demanding reaction. It generates homocysteine from the methyl



Número de artículo de comercio global

SKUGTIN
1420006-50MG04061833860533